InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (8 ops.)
Discover the complete record of transactions filed by Obenshain Andrew, President of SGD. Insider active across 1 companies, notably bluebird bio, Inc.. Cumulatively, 14 reports have been published. Total volume traded: €56k. The latest transaction was filed on 1 February 2022 — Attribution. Regulator: SEC (Form 4). All data is accessible without signup.
Declarations14 total
018,000 shares0
Common Stock
SEC:0001562180-22-001088·
018,000 shares0
Common Stock
SEC:0001562180-22-001088:0·
€6,937852 shares@ €8.142125.3% of flow
Common Stock
SEC:0001562180-22-000441·
€6,937852 shares@ €8.142112.5% of flow
Common Stock
SEC:0001562180-22-000441:0·
€7,504832 shares@ €9.018927.4% of flow
Common Stock
SEC:0001562180-21-007594·
€7,504832 shares@ €9.018913.5% of flow
Common Stock
SEC:0001562180-21-007594:0·
0586 shares0
Common Stock
SEC:0001628280-21-023644·
0586 shares0
Common Stock
SEC:0001628280-21-023644:0·
0100,000 shares0
Common Stock
SEC:0001562180-21-005170·
0100,000 shares0
Common Stock
SEC:0001562180-21-005170:0·
€12,952511 shares@ €25.347347.3% of flow
Common Stock
SEC:0001562180-21-004132·
€12,952511 shares@ €25.347323.3% of flow
Common Stock
SEC:0001562180-21-004132:0·
€72529 shares@ €24.99831.3% of flow
Common Stock
SEC:0001562180-21-003233:0·
29 shares
Common Stock
SEC:0001562180-21-003233·
14 of 14 declarations
About Obenshain Andrew
Andrew Obenshain is the Chief Executive Officer of bluebird bio, Inc. He leads the company with a focus on innovation in gene therapies. His role includes overseeing operations and implementing strategies to achieve the company's objectives.
